Biomarkers of human gut microbiota diversity and dysbiosis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell. Microbiol. 16(7), 1024–1033 (2014). •• This review article is a wonderful introduction into the topic of dysbiosis of the microbial ecosystem, how it is triggered by external influences and which effects dysbiosis has on hosts health and immune regulation.
  Medline CASGoogle Scholar
• 2. Branchereau M, Burcelin R, Heymes C. The gut microbiome and heart failure: a better gut for a better heart. Rev. Endocr. Metab. Disord. 20(4), 407–414 (2019).
  MedlineGoogle Scholar
• 3. Brown EG, Tanner CM, Goldman SM. The microbiome in neurodegenerative disease. Curr. Geriatr. Rep. 7(2), 81–91 (2018).
  Google Scholar
• 4. Chen J, Chia N, Kalari KR et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci. Rep. 6(1), 1–10 (2016).
  MedlineGoogle Scholar
• 5. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9(5), 313–323 (2009).
  Medline CASGoogle Scholar
• 6. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J. Clin. Invest. 121(6), 2126–2132 (2011).
  Medline CASGoogle Scholar
• 7. Clarke SF, Murphy EF, O'sullivan O et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63(12), 1913–1920 (2014).
  Medline CASGoogle Scholar
• 8. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505(7484), 559–563 (2014).
  Medline CASGoogle Scholar
• 9. Koeth RA, Wang Z, Levison BS et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19(5), 576–585 (2013).
  Medline CASGoogle Scholar
• 10. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472(7341), 57–63 (2011).
  Medline CASGoogle Scholar
• 11. Wang Z, Roberts AB, Buffa JA et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163(7), 1585–1595 (2015).
  Medline CASGoogle Scholar
• 12. Al-Obaide MA, Singh R, Datta P et al. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J. Clin. Med. 6(9), 86 (2017).
  Google Scholar
• 13. Cho CE, Taesuwan S, Malysheva OV et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol. Nutr. Food Res. 61(1), 1600324 (2017).
  Google Scholar
• 14. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients 10(10), 1398 (2018). • Presents the endogenous synthesis of trimethylamine-N-oxide within microbial metabolism. It explains the potential effects of trimethylamine-N-oxide on immune functions and the etiology of cardiovascular as well as neurological disorders and is therefore an excellent introduction to the topic.
  Google Scholar
• 15. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins 8(11), 326 (2016).
  Google Scholar
• 16. Sanchez-Alcoholado L, Castellano-Castillo D, Jordán-Martínez L et al. Role of gut microbiota on cardio-metabolic parameters and immunity in coronary artery disease patients with and without type-2 diabetes mellitus. Front. Microbiol. 8, 1936 (2017).
  MedlineGoogle Scholar
• 17. Xu K-Y, Xia G-H, Lu J-Q et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci. Rep. 7(1), 1–12 (2017).
  MedlineGoogle Scholar
• 18. Yin J, Liao SX, He Y et al. Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J. Am. Heart Assoc. 4(11), e002699 (2015).
  MedlineGoogle Scholar
• 19. Falony G, Vieira-Silva S, Raes J. Microbiology meets big data: the case of gut microbiota–derived trimethylamine. Annu. Rev. Microbiol. 69, 305–321 (2015).
  Medline CASGoogle Scholar
• 20. Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De Los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Front. Microbiol. 7, 185 (2016).
  MedlineGoogle Scholar
• 21. Zeng H, Lazarova DL, Bordonaro M. Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J. Gastrointest. Oncol. 6(2), 41 (2014).
  MedlineGoogle Scholar
• 22. Sorbara MT, Dubin K, Littmann ER et al. Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification. J. Exp. Med. 216(1), 84–98 (2019). •• This article is particularly relevant in the context of understanding colonization resistance and the process of colonization with multiresistant pathogens. It reveals that commensal microbiota-derived metabolites, such as short-chain fatty acids, are involved in immunity against pathogenic organisms.
  Medline CASGoogle Scholar
• 23. La Cuesta-Zuluaga D, Mueller NT, Álvarez-Quintero R et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients 11(1), 51 (2019).
  Google Scholar
• 24. Vogt JA, Wolever TM. Fecal acetate is inversely related to acetate absorption from the human rectum and distal colon. J. Nutr. 133(10), 3145–3148 (2003).
  Medline CASGoogle Scholar
• 25. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81, 1031–1064 (2001). •• Topping and Clifton provide here a very detailed and interesting overview of the importance of short-chain fatty acids for GI tract functions and its effects on physiological functions. This article is particularly suitable for nutritionists but also for other scientists interested in the metabolic functions of the intestinal microbiome.
  Medline CASGoogle Scholar
• 26. Sun Q, Jia Q, Song L, Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: a systematic review and meta-analysis. Medicine 98(7), e14513 (2019).
  Medline CASGoogle Scholar
• 27. Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin. Chem. 59(4), 617–628 (2013).
  Medline CASGoogle Scholar
• 28. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J. Nutr. 132(5), 1012–1017 (2002).
  Medline CASGoogle Scholar
• 29. Kelly CJ, Zheng L, Campbell EL et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17(5), 662–671 (2015).
  Medline CASGoogle Scholar
• 30. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12(10), 661–672 (2014).
  Medline CASGoogle Scholar
• 31. Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. In: Dietary Fiber in Health and Disease. Springer, MA, USA, 123–134 (1997).
  Google Scholar
• 32. Yan J, Herzog JW, Tsang K et al. Gut microbiota induce IGF-1 and promote bone formation and growth. Proc. Natl Acad. Sci. USA 113(47), E7554–E7563 (2016).
  Medline CASGoogle Scholar
• 33. Wang T, Cai G, Qiu Y et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6(2), 320–329 (2012).
  Medline CASGoogle Scholar
• 34. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE 8(8), e70803 (2013).
  Medline CASGoogle Scholar
• 35. Sze MA, Topçuoğlu BD, Lesniak NA, Ruffin MT, Schloss PD. Fecal short-chain fatty acids are not predictive of colonic tumor status and cannot be predicted based on bacterial community structure. mBio 10(4), e01454–e01419 (2019).
  Medline CASGoogle Scholar
• 36. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4), 913–916.e917 (2012).
  Medline CASGoogle Scholar
• 37. Müller M, Hernández MaG, Goossens GH et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci. Rep. 9(1), 1–9 (2019).
  MedlineGoogle Scholar
• 38. Rowland I, Gibson G, Heinken A et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur. J. Nutr. 57(1), 1–24 (2018).
  Medline CASGoogle Scholar
• 39. Banoglu E, King R. Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet. 27(2), 135–140 (2002).
  Medline CASGoogle Scholar
• 40. Weber D, Oefner PJ, Hiergeist A et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood 126(14), 1723–1728 (2015).
  Medline CASGoogle Scholar
• 41. Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl sulfate. Toxins 9(2), 52 (2017).
  Google Scholar
• 42. Lin C-J, Wu V, Wu P-C, Wu C-J. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS ONE 10(7), e0132589 (2015).
  MedlineGoogle Scholar
• 43. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J. Am. Soc. Nephrol. 25(9), 1897–1907 (2014).
  Medline CASGoogle Scholar
• 44. Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease-and uricase-containing, indole-and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 39(3), 230–237 (2014).
  Medline CASGoogle Scholar
• 45. Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15(7), 804 (2009).
  Medline CASGoogle Scholar
• 46. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32(Suppl. 2), S237–S245 (2009).
  Medline CASGoogle Scholar
• 47. Ridlon JM, Harris SC, Bhowmik S, Kang D-J, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7(1), 22–39 (2016).
  Medline CASGoogle Scholar
• 48. Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease. Mediators Inflammation 2019, 13 (2019).
  Google Scholar
• 49. Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, Type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152(7), 1679–1694. e1673 (2017).
  Medline CASGoogle Scholar
• 50. Gottlieb A, Canbay A. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression. Cells 8(11), 1358 (2019).
  CASGoogle Scholar
• 51. Lajczak NK, Saint-Criq V, O'dwyer AM et al. Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and-2 secretion by colonic epithelial cells. FASEB J. 31(9), 3848–3857 (2017).
  Medline CASGoogle Scholar
• 52. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into non-alcoholic fatty liver disease and its progression. Curr. Opin. Gastroenterol. 28(2), 159 (2012).
  Medline CASGoogle Scholar
• 53. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol. Rev. 29(4), 625–651 (2005).
  Medline CASGoogle Scholar
• 54. Antharam VC, Li EC, Ishmael A et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51(9), 2884–2892 (2013).
  MedlineGoogle Scholar
• 55. Buffie CG, Bucci V, Stein RR et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517(7533), 205–208 (2015). • Using mathematical modeling and various statistical analyses, it is shown here that secondary bile acids could be a potential approach to Clostridioides difficile infection recurrence prophylaxis and which microorganisms are important in this context.
  Medline CASGoogle Scholar
• 56. Khanna S, Pardi DS, Kelly CR et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214(2), 173–181 (2016).
  MedlineGoogle Scholar
• 57. Theriot CM, Bowman AA, Young VB. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. MSphere 1(1), e00045–e00115 (2016).
  Medline CASGoogle Scholar
• 58. Pallister T, Jackson MA, Martin TC et al. Hippurate as a metabolomic marker of gut microbiome diversity: modulation by diet and relationship to metabolic syndrome. Sci. Rep. 7(1), 1–9 (2017). •• Provides an extensive profiling of various metabolic markers and identifies hippurate as marker of microbial diversity and possible marker of metabolic disorders. Many important findings of this work are summarized in our review article.
  Medline CASGoogle Scholar
• 59. Gatley SJ, Sherratt HSA. The localization of hippurate synthesis in the matrix of rat liver mitochondria. Biochem Soc Trans 4(3), 525–526 (1976).
  Medline CASGoogle Scholar
• 60. Dall'asta M, Calani L, Tedeschi M, Jechiu L, Brighenti F, Del Rio D. Identification of microbial metabolites derived from in vitro fecal fermentation of different polyphenolic food sources. Nutrition 28(2), 197–203 (2012).
  MedlineGoogle Scholar
• 61. Lees HJ, Swann JR, Wilson ID, Nicholson JK, Holmes E. Hippurate: the natural history of a mammalian–microbial cometabolite. J. Proteome Res. 12(4), 1527–1546 (2013).
  Medline CASGoogle Scholar
• 62. Edberg SC, Samuels S. Rapid, colorimetric test for the determination of hippurate hydrolysis by group B Streptococcus. J. Clin. Microbiol. 3(1), 49–50 (1976).
  Medline CASGoogle Scholar
• 63. Ziegler P, Kutzner H. Hippurate hydrolysis as a taxonomic criterion in the genus Streptomyces (order Actinomycetales). Zeitschrift für allgemeine Mikrobiologie 13(3), 265–272 (1973).
  Medline CASGoogle Scholar
• 64. Swann JR, Tuohy KM, Lindfors P et al. Variation in antibiotic-induced microbial recolonization impacts on the host metabolic phenotypes of rats. J. Proteome Res. 10(8), 3590–3603 (2011).
  Medline CASGoogle Scholar
• 65. Yap IK, Li JV, Saric J et al. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J. Proteome Res. 7(9), 3718–3728 (2008).
  Medline CASGoogle Scholar
• 66. Joossens M, Huys G, Cnockaert M et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60(5), 631–637 (2011).
  MedlineGoogle Scholar
• 67. Williams HR, Cox IJ, Walker DG et al. Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn’s disease. BMC Gastroenterol. 10(1), 108 (2010).
  MedlineGoogle Scholar
• 68. Schröder J-M, Harder J. Human beta-defensin-2. Int. J. Biochem. Cell Biol. 31(6), 645–651 (1999).
  Medline CASGoogle Scholar
• 69. Niyonsaba F, Ogawa H, Nagaoka I. Human β-defensin-2 functions as a chemotactic agent for tumour necrosis factor-α-treated human neutrophils. Immunology 111(3), 273–281 (2004).
  Medline CASGoogle Scholar
• 70. Takahashi A, Wada A, Ogushi K-I et al. Production of β-defensin-2 by human colonic epithelial cells induced by Salmonella enteritidis flagella filament structural protein. FEBS Lett. 508(3), 484–488 (2001).
  Medline CASGoogle Scholar
• 71. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schröder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J. Biol. Chem. 281(4), 2005–2011 (2006).
  Medline CASGoogle Scholar
• 72. Schlee M, Harder J, Köten B, Stange E, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL# 3 induce enterocyte β-defensin 2. Clin. Exp. Immunol. 151(3), 528–535 (2008).
  Medline CASGoogle Scholar
• 73. Wehkamp J, Schmidt K, Herrlinger K et al. Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status. J. Clin. Pathol. 56(5), 352–357 (2003).
  Medline CASGoogle Scholar
• 74. Wehkamp J, Harder J, Wehkamp K et al. NF-κB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. 72(10), 5750–5758 (2004).
  Medline CASGoogle Scholar
• 75. Möndel M, Schroeder B, Zimmermann K et al. Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2(2), 166–172 (2009).
  Medline CASGoogle Scholar
• 76. Kapel N, Benahmed N, Morali A et al. Fecal β-defensin-2 in children with inflammatory bowel diseases. J. Pediatr. Gastroenterol. Nutr. 48(1), 117–120 (2009).
  Medline CASGoogle Scholar
• 77. Coretti L, Natale A, Cuomo M et al. The interplay between defensins and microbiota in Crohn’s disease. Mediators Inflammation 2017, 8 (2017).
  Google Scholar
• 78. Gutierrez A, Holler E, Zapater P et al. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn’s disease is affected by NOD2/CARD15 genotype. Inflamm. Bowel Dis. 17(8), 1641–1650 (2011).
  MedlineGoogle Scholar
• 79. D'amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr. Connect. 3(2), R45–R54 (2014).
  MedlineGoogle Scholar
• 80. Sundin J, Stridsberg M, Tap J et al. Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects. Sci. Rep. 8(1), 1–13 (2018).
  Medline CASGoogle Scholar
• 81. Shooshtarizadeh P, Zhang D, Chich J-F et al. The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regul. Pept. 165(1), 102–110 (2010).
  Medline CASGoogle Scholar
• 82. Conlon JM, Demandt A, Nielsen PF, Leprince J, Vaudry H, Woodhams DC. The alyteserins: two families of antimicrobial peptides from the skin secretions of the midwife toad Alytes obstetricans (Alytidae). Peptides 30(6), 1069–1073 (2009).
  Medline CASGoogle Scholar
• 83. O'toole D, Grossman A, Gross D et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 90(2), 194–202 (2009).
  MedlineGoogle Scholar
• 84. Bartolomucci A, Pasinetti G, Salton S. Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 170(1), 289–297 (2010).
  Medline CASGoogle Scholar
• 85. Ottesen AH, Christensen G, Omland T, Røsjø H. Glycosylated chromogranin A: potential role in the pathogenesis of heart failure. Curr. Heart Fail. Rep. 14(6), 478–488 (2017).
  Medline CASGoogle Scholar
• 86. Zhernakova A, Kurilshikov A, Bonder MJ et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352(6285), 565–569 (2016).
  Medline CASGoogle Scholar
• 87. Ghavami SB, Rostami E, Sephay AA et al. Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases. Microb. Pathog. 117, 285–289 (2018).
  Medline CASGoogle Scholar
• 88. Cerutti A. The regulation of IgA class switching. Nature Rev. Immunol. 8(6), 421–434 (2008).
  Medline CASGoogle Scholar
• 89. Mantis NJ, Rol N, Corthésy B. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4(6), 603–611 (2011).
  Medline CASGoogle Scholar
• 90. Peterson DA, Mcnulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe 2(5), 328–339 (2007).
  Medline CASGoogle Scholar
• 91. Maes M, Mihaylova I, Leunis J-C. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut–intestinal permeability. J. Affect. Disord. 99(1–3), 237–240 (2007).
  Medline CASGoogle Scholar
• 92. Bischoff SC, Barbara G, Buurman W et al. Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. 14(1), 189 (2014).
  MedlineGoogle Scholar
• 93. Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology 153(3), 723–731. e721 (2017).
  MedlineGoogle Scholar
• 94. Maes M, Kubera M, Leunis J-C, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J. Affect. Disord. 141(1), 55–62 (2012).
  Medline CASGoogle Scholar
• 95. Sjögren YM, Tomicic S, Lundberg A et al. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses: gut microbiota and immune responses. Clin. Exp. Allergy 39(12), 1842–1851 (2009).
  Medline CASGoogle Scholar
• 96. Spencer SP, Fragiadakis GK, Sonnenburg JL. Pursuing human-relevant gut microbiota-immune interactions. Immunity 51(2), 225–239 (2019).
  Medline CASGoogle Scholar
• 97. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann. NY Acad. Sci. 1258(1), 25 (2012).
  Medline CASGoogle Scholar
• 98. El Asmar R, Panigrahi P, Bamford P et al. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 123(5), 1607–1615 (2002).
  MedlineGoogle Scholar
• 99. Vanuytsel T, Vermeire S, Cleynen I. The role of haptoglobin and its related protein, zonulin, in inflammatory bowel disease. Tissue Barriers 1(5), e27321 (2013).
  MedlineGoogle Scholar
• 100. Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 4(4), e1251384 (2016).
  MedlineGoogle Scholar
• 101. Klaus DA, Motal MC, Burger-Klepp U et al. Increased plasma zonulin in patients with sepsis. Biochem. Med. 23(1), 107–111 (2013).
  CASGoogle Scholar
• 102. Li X, Atkinson MA. The role for gut permeability in the pathogenesis of Type 1 diabetes–a solid or leaky concept? Pediatr. Diabetes 16(7), 485–492 (2015).
  MedlineGoogle Scholar
• 103. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 8(1), 1–12 (2016).
  MedlineGoogle Scholar
• 104. Durazzo M, Ferro A, Gruden G. Gastrointestinal microbiota and Type 1 diabetes mellitus: the state of art. J. Clin. Med. 8(11), 1843 (2019).
  CASGoogle Scholar
• 105. Frati F, Salvatori C, Incorvaia C et al. The role of the microbiome in asthma: the gut–lung axis. Int. J. Mol. Sci. 20(1), 123 (2019).
  Google Scholar
• 106. Iacob S, Iacob DG. Infectious threats, the intestinal barrier, and its Trojan horse: dysbiosis. Front.Microbiol. 10, 10 (2019).
  MedlineGoogle Scholar
• 107. Mörkl S, Lackner S, Meinitzer A et al. Gut microbiota, dietary intakes and intestinal permeability reflected by serum zonulin in women. Eur. J. Nutr. 57(8), 2985–2997 (2018).
  Medline CASGoogle Scholar
• 108. Liu Z-H, Huang M-J, Zhang X-W et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am. J. Clin. Nutr. 97(1), 117–126 (2013).
  Medline CASGoogle Scholar